Sood, Anil K.

Selected publications

Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach. Gynecologic Oncology. 2017 Academic Article GET IT
Times cited: 8
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016 Review GET IT
Times cited: 2159
Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: emerging therapies in gynecologic cancer. Gynecologic Oncology. 2014 Article GET IT
Times cited: 3
Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clinical Cancer Research. 2013 Academic Article GET IT
Times cited: 46
Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clinical Cancer Research. 2012 Academic Article GET IT
Times cited: 30
Proceedings from the 9th International Conference on Ovarian Cancer. Gynecologic Oncology. 2012 Article GET IT
Times cited: 1
Inverse relationship between TCTP/RhoA and p53//cyclin A/actin expression in ovarian cancer cells. Folia Histochemica et Cytobiologica. 2012 Academic Article GET IT
Times cited: 13
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. The Lancet Oncology. 2011 Academic Article GET IT
Times cited: 79
Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecologic Oncology. 2011 Academic Article GET IT
Times cited: 65
Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biology and Therapy. 2010 Academic Article GET IT
Times cited: 36
Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. Journal of Clinical Investigation. 2010 Academic Article GET IT
Times cited: 153
Plasma cell-free DNA in ovarian cancer: An independent prognostic biomarker. Cancer. 2010 Academic Article GET IT
Times cited: 81
Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Molecular Cancer Therapeutics. 2010 Academic Article GET IT
Times cited: 37
Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biology and Therapy. 2009 Academic Article GET IT
Times cited: 34
EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer. 2009 Academic Article GET IT
Times cited: 40
Functional significance of VEGFR-2 on ovarian cancer cells. International Journal of Cancer. 2009 Academic Article GET IT
Times cited: 85
Dicer, Drosha, and outcomes in patients with ovarian cancer. New England Journal of Medicine. 2008 Academic Article GET IT
Times cited: 523
Tumor-selective response to antibody-mediated targeting of αvβ3 integrin in ovarian cancer. Neoplasia (United States). 2008 Academic Article GET IT
Times cited: 86
Targeting Aurora kinase with MK-0457 inhibits ovarian cancer growth. Clinical Cancer Research. 2008 Academic Article GET IT
Times cited: 53
HLA class i antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clinical Cancer Research. 2008 Academic Article GET IT
Times cited: 97
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. Journal of the National Cancer Institute. 2008 Academic Article GET IT
Times cited: 189
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. Journal of the National Cancer Institute. 2008 Academic Article GET IT
Times cited: 124
Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clinical Cancer Research. 2007 Academic Article GET IT
Times cited: 130
Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Research. 2007 Academic Article GET IT
Times cited: 159
Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Research. 2007 Academic Article GET IT
Times cited: 101
Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Research. 2007 Academic Article GET IT
Times cited: 66
Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clinical Cancer Research. 2007 Academic Article GET IT
Times cited: 69
Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-κB pathway. Clinical Cancer Research. 2007 Academic Article GET IT
Times cited: 287
Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Research. 2007 Academic Article GET IT
Times cited: 142
EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer. 2007 Academic Article GET IT
Times cited: 80
Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Research. 2007 Academic Article GET IT
Times cited: 117
Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biology and Therapy. 2006 Academic Article GET IT
Times cited: 81
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. Journal of the National Cancer Institute. 2006 Academic Article GET IT
Times cited: 100
Analysis of EphA2 expression and mutant p53 in ovarian carcinoma. Cancer Biology and Therapy. 2006 Academic Article GET IT
Times cited: 14
Circulating cell-free DNA: A novel biomarker for response to therapy in ovarian carcinoma. Cancer Biology and Therapy. 2006 Academic Article GET IT
Times cited: 76
Antiangiogenic and antitumor effects of Src inhibition in ovarian carcinoma. Cancer Research. 2006 Academic Article GET IT
Times cited: 68
Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR. Annals of the New York Academy of Sciences. 2006 Academic Article GET IT
Times cited: 41
Focal adhesion kinasetargeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clinical Cancer Research. 2006 Academic Article GET IT
Times cited: 266
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nature Medicine. 2006 Academic Article GET IT
Times cited: 673
The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clinical Cancer Research. 2006 Academic Article GET IT
Times cited: 141
Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. Journal of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 56
Stress hormone-mediated invasion of ovarian cancer cells. Clinical Cancer Research. 2006 Academic Article GET IT
Times cited: 317
The role of relaxin in endometrial cancer. Cancer Biology and Therapy. 2006 Academic Article GET IT
Times cited: 45
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Research. 2005 Academic Article GET IT
Times cited: 241
The merits of vascular targeting for gynecologic malignancies. Current Oncology Reports. 2005 Review GET IT
Times cited: 3
Fifth International Conference on Ovarian Cancer: Challenges and opportunities. Gynecologic Oncology. 2005 Article GET IT
Times cited: 10

VIVO Weill Cornell Medical College

Sood, Anil K. External Author

Publications

Selected publications